Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT200 in Recurrent or Metastatic Triple-Negative Breast Cancer
CTR20180903Phase 2Completed
- Sponsor
- Shenzhou Cell Engineering Co., Ltd.
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of sct200 in breast cancer, sponsored by Shenzhou Cell Engineering Co., Ltd.. Started Jul 2018; status: completed.
02
Drugs
sct200
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20180903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180903.